Homburger advised Santhera Pharmaceuticals on its entrance into a royalty monetization financing totaling up to USD 38 m with R-Bridge, an affiliate of CBC Group, amongst Asia’s largest healthcare-focused investment firms. Santhera is monetizing 75% of
Homburger advised ADC Therapeutics, a commercial-stage biotechnology company producing antibody drug conjugates (ADCs) for cancer patients, on its 13.4 m of common shares, and, to certain investors who so choose in lieu of common shares, pre-funded
Wöhrle Group, headquartered in Wildberg, Germany, has announced that it had acquired the Swiss Oskar Rüegg Holding and its subsidiaries (Switzerland / Bulgaria / Mexico). Both companies specialize in the manufacture of sophisticated stamped parts
Novartis hands over the Life-Science-Park Rhine Valley to GETEC Switzerland, the platform of a leading European energy supplier and contracting specialist GETEC Group. They are the new owner and operator of the properties and infrastructure
Santhera Pharmaceuticals Holding has completed a 10:1 reverse split of its shares, which had been approved by the shareholders on June 27, 2023, with the listing and first day of trading of the post-split shares on the SIX
Homburger has provided legal counsel to Santhera Pharmaceuticals Holding (SIX: SANN “Santhera”) on its completion of a 10:1 reverse split of its shares. The reverse split, which was approved by shareholders on June 27, 2023, resulted in the
Migros has announced a series of steps in its plan to bundle its supermarket business into a centrally managed stand-alone company, Migros Supermarkt. This business represented CHF 12 billion in revenues by 2022. Migros Supermarkt is scheduled
As part of a strategic reorganization, the American cotton manufacturer U.S. Cotton has sold the Flawil-based producer of absorbent cotton and other products, FLAWA Consumer, to members of its management. Homburger advised U.S.
Santhera Pharmaceuticals Holding has announced the grant of an exclusive North America license for the commercialization of vamorolone to Catalyst Pharmaceuticals for a total consideration of up to USD 231 million
Santhera Pharmaceuticals Holding announced a private placement of shares and an amendment of its existing financing with funds managed by Highbridge Capital Management to provide up to CHF 22.2 million in aggregate, subject to certain milestones
